Semaglutide (Ozempic®/Wegovy®): Mechanism, Studies & Calculator

Pharmacology and molecular structure of Semaglutide

Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), an incretin hormone produced by intestinal L cells in response to food intake. The molecule was engineered by Novo Nordisk to resist degradation by dipeptidyl peptidase-4 (DPP-4) and drastically extend plasma half-life compared to endogenous GLP-1, which has a half-life of only 1-2 minutes.

Three major modifications confer Semaglutide its unique pharmacokinetic profile: (1) amino acid 8 substitution (alanine → α-aminoisobutyric acid) preventing DPP-4 cleavage; (2) amino acid 34 substitution (lysine → arginine) altering structural stability; (3) attachment of a C18 diacid fatty acid side chain via a γGlu-2xOEG spacer at lysine 26, enabling reversible high-affinity binding to serum albumin. This albumin binding protects the molecule from renal filtration and extends plasma half-life to approximately 165-184 hours (~1 week), enabling weekly dosing.

Subcutaneous bioavailability is approximately 89%, with plasma peak 1-3 days after injection. Steady state is reached after 4-5 weeks of consistent weekly dosing. Elimination occurs predominantly through proteolytic metabolism followed by renal and fecal excretion of metabolites, without substantial CYP450 dependence, reducing significant drug-drug interactions.

The oral formulation (Rybelsus®) employs the absorption enhancer SNAC (sodium salcaprozate), which transiently raises local gastric pH and enables absorption through the epithelium. Oral bioavailability is substantially lower (~1%), requiring daily dosing, at least 30 minutes of fasting beforehand, and reduced water volumes at administration.

Mechanism of action: from GLP-1 receptors to central appetite control

Semaglutide acts as a selective GLP-1 receptor (GLP-1R) agonist, a G-protein coupled receptor (class B GPCR) expressed in multiple tissues: pancreatic β cells, central nervous system, gastrointestinal tract, kidneys, heart, and immune system. Signaling primarily involves the Gαs/adenylate cyclase/cAMP/PKA pathway, with subsequent stimulation of secondary pathways such as EPAC, PI3K, and MAPK/ERK.

In the pancreas, GLP-1R activation promotes insulin secretion in a glucose-dependent manner — meaning the stimulus occurs only when glycemia is elevated, which explains semaglutide's low intrinsic hypoglycemia risk in monotherapy. In parallel, it suppresses glucagon secretion from pancreatic α cells, reduces β cell apoptosis in preclinical models, and may increase β cell mass in animal studies.

In the gastrointestinal tract, semaglutide delays gastric emptying and reduces intestinal motility, contributing to increased postprandial satiety. This effect is most pronounced in the first weeks of treatment and tends to attenuate over time (partial tachyphylaxis), although appetite reduction persists.

Central effects on appetite and food intake are mediated by direct action on brain regions permeable to the molecule (circumventricular organs, such as area postrema and median eminence) and by active transport and diffusion across the blood-brain barrier. Main targets include POMC/CART neurons of the hypothalamic arcuate nucleus, area postrema (medulla), nucleus tractus solitarius, and mesolimbic reward circuits. The result is increased satiety, reduced hunger, decreased perceived palatability of hypercaloric foods, and attenuation of the so-called "cerebral food noise" subjectively reported by many patients on chronic use.

STEP trials: obesity without diabetes

The STEP (Semaglutide Treatment Effect in People with obesity) program included multiple phase III trials that supported Wegovy® approval for chronic weight management. All used a 2.4 mg subcutaneous weekly maintenance dose after a 16-week titration phase.

In STEP 1 (Wilding et al., NEJM 2021), 1,961 adults with BMI ≥30 (or ≥27 with comorbidity) without diabetes were randomized 2:1 to semaglutide 2.4 mg or placebo, both with lifestyle intervention. At 68 weeks, the semaglutide group showed mean weight loss of 14.9% vs 2.4% on placebo (difference −12.4 percentage points; p < 0.001). The ≥5% weight loss endpoint was achieved by 86.4% vs 31.5%, and ≥20% by 32.0% vs 1.7%.

STEP 3 added intensive behavioral therapy in both arms, confirming incremental benefit. STEP 4 evaluated maintenance: after 20 weeks on semaglutide, patients were re-randomized to continue or switch to placebo. Those continuing lost an additional 7.9%; those switching regained 6.9%. This positioned obesity as a chronic disease requiring continuous treatment.

STEP 5 extended follow-up to 104 weeks (2 years), demonstrating maintenance of −15.2% vs +2.6% on placebo. STEP 8 directly compared semaglutide 2.4 mg vs liraglutide 3.0 mg, with marked semaglutide superiority (−15.8% vs −6.4%). STEP TEENS validated use in adolescents (12-17 years) with efficacy and safety profile compatible with adults.

SUSTAIN trials: type 2 diabetes

The SUSTAIN program provided the basis for Ozempic® approval in type 2 diabetes and included active comparisons with other glucose-lowering agents. In SUSTAIN 1-5, semaglutide reduced HbA1c by 1.1-1.8% versus 0.1-1.2% with comparators (placebo, sitagliptin, exenatide LAR, insulin glargine), with additional weight loss of 3-6 kg.

SUSTAIN 6 (Marso et al., NEJM 2016) was the pivotal cardiovascular trial: 3,297 patients with T2D and high CV risk randomized to semaglutide 0.5 or 1.0 mg or placebo, followed for 104 weeks. The primary MACE-3 endpoint (CV death, non-fatal MI or stroke) occurred in 6.6% (semaglutide) vs 8.9% (placebo), HR 0.74; 95% CI 0.58-0.95; p < 0.001 for non-inferiority and p = 0.02 for superiority, driven primarily by reduction in non-fatal stroke.

A relevant safety signal was increased diabetic retinopathy in SUSTAIN 6 (3.0% vs 1.8%; HR 1.76), possibly related to rapid glycemic improvement in patients with poorly controlled pre-existing retinopathy — a phenomenon analogous to that described with intensive insulin therapy. Decompensated proliferative retinopathy remains a risk population requiring ophthalmologic assessment before initiation.

SELECT trial: cardiovascular prevention in obesity without diabetes

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was one of the most influential trials in recent metabolic cardiology. Published by Lincoff et al. in NEJM in November 2023, it randomized 17,604 adults ≥45 years with BMI ≥27 and established cardiovascular disease (post-MI, post-stroke, or symptomatic peripheral arterial disease), without diabetes, to semaglutide 2.4 mg or placebo.

After a mean follow-up of 39.8 months, the primary endpoint (MACE-3) occurred in 6.5% in the semaglutide group vs 8.0% on placebo: HR 0.80 (95% CI 0.72-0.90; p < 0.001). The NNT over the trial was approximately 67. Secondary analyses showed consistent benefit across endpoint components, reduction in heart failure hospitalization, improved renal function, and sustained mean weight reduction of 9.4%.

This was the first trial to demonstrate that a GLP-1 RA reduces cardiovascular events in patients with obesity without diabetes — a result with implications for secondary prevention guidelines. The FDA formally added the MACE risk reduction indication to the Wegovy® label in March 2024.

Adverse events, contraindications, and monitoring

The most common adverse events described in STEP and SUSTAIN trials are predominantly gastrointestinal and typically mild to moderate: nausea (~44%), diarrhea (~30%), constipation (~24%), vomiting (~24%), dyspepsia, and abdominal pain. Their intensity is greater during titration and tends to decrease after 8-12 weeks. Described mitigation strategies include smaller meals, adequate hydration, and slower titration when needed.

Less frequent but clinically relevant adverse events include cholelithiasis (especially with rapid weight loss), acute pancreatitis (a signal present in pooled analyses, though without statistically significant increase), hypoglycemia (rare in monotherapy; increased when associated with sulfonylureas or insulin), injection site reactions, and, in specific contexts, paralytic ileus and gastroparesis.

Label-described absolute contraindications include: personal or family history of medullary thyroid carcinoma (based on a signal in rodent models with C-cell activation), multiple endocrine neoplasia syndrome type 2 (MEN2), and known hypersensitivity. Individualized caution is required in prior pancreatitis, proliferative diabetic retinopathy, severe renal impairment (eGFR <15), pregnancy, and lactation.

Monitoring described in the literature includes: weight, waist circumference, blood pressure, HbA1c (if diabetic), lipid panel, renal function (creatinine, eGFR), liver function, occasionally amylase/lipase if symptoms compatible with pancreatitis, and ophthalmologic assessment in patients with known diabetic retinopathy. Individualization remains essential.

Semaglutide versus Tirzepatide: evidence-based comparison

Tirzepatide (Mounjaro® for T2D, Zepbound® for weight management) is a dual GLP-1 and GIP receptor agonist developed by Eli Lilly. Additional GIP activity appears to complement the GLP-1 effect, contributing to insulin sensitization and complementary lipolytic effects in adipose tissue.

SURPASS-2 (Frías et al., NEJM 2021) was the most relevant head-to-head comparison between the two molecules in T2D: it randomized 1,879 patients to semaglutide 1 mg or tirzepatide 5, 10, or 15 mg weekly. At 40 weeks, tirzepatide 15 mg reduced HbA1c by 2.30% vs 1.86% with semaglutide (difference -0.45 percentage points; p < 0.001) and weight by 11.2 kg vs 5.7 kg (difference -5.5 kg).

In the SURMOUNT program (obesity), tirzepatide 15 mg at 72 weeks produced mean weight loss of 22.5% (vs 14.9% with semaglutide in STEP 1 — indirect comparison). SURMOUNT-5, published in 2025, directly compared tirzepatide vs semaglutide in obesity without diabetes and confirmed tirzepatide superiority.

From a cardiovascular perspective, tirzepatide still lacked a complete CVOT equivalent to SELECT at the time of last review, with SURPASS-CVOT results expected for 2024-2025. The choice between molecules involves efficacy, tolerability profile, cost, local availability, specific CV evidence, and individual patient particularities.

Compounded Semaglutide vs brand pharmaceutical product

During the Ozempic® and Wegovy® shortages between 2022-2024, compounding pharmacies in the United States began preparing semaglutide versions to meet demand. Legally, 503A/503B of the Food Drug and Cosmetic Act allow compounding only during officially FDA-declared shortage periods. In October 2024, the FDA removed semaglutide from the shortage list, and continued compounding became the subject of regulatory dispute.

From a scientific perspective, the brand pharmaceutical product (Novo Nordisk) has rigorously validated pharmacokinetics, chemical purity, absence of related impurities, and batch-to-batch consistency under international GMP standards and submitted to FDA/EMA/Anvisa. Compounded versions may involve: untraceable raw material sources, lack of bioequivalence studies, variability of actual vs labeled concentration, inclusion of alternative excipients (e.g., pyridoxine/B6 in "sema+B6"), and absence of equivalent oversight.

FDA MedWatch reports document cases of overdose from dilution errors, local reactions, and severe gastrointestinal adverse events associated with compounded products. The literature emphasizes the need for verifiable sourcing, documented pharmacokinetic information, and rigorous clinical follow-up.

Titration schedules described in label

Slow titration is the central strategy described in label to mitigate class-characteristic gastrointestinal events. For Wegovy® (weight management), the described schedule starts at 0.25 mg/week for 4 weeks, followed by 0.5 mg (weeks 5-8), 1.0 mg (weeks 9-12), 1.7 mg (weeks 13-16), and maintenance dose 2.4 mg/week from week 17 onward.

For Ozempic® (T2D), the standard schedule is 0.25 mg (weeks 1-4), 0.5 mg (weeks 5-8), with option to increase to 1.0 mg if glycemic control is insufficient and, in some markets, 2.0 mg as an additional maximum dose. For Rybelsus® (oral), the schedule starts at 3 mg/day for 30 days, followed by 7 mg/day and, if needed, 14 mg/day.

The literature describes flexibility in the schedule when intolerance occurs: extending each step from 4 to 8 weeks, returning to a lower dose with a new escalation attempt, or maintaining at an effective submaximal dose. Individualization remains the guiding principle.

Discontinuation and weight regain

One of the most important findings from STEP 4 was the unequivocal demonstration that Semaglutide discontinuation results in gradual and progressive weight regain. Of participants who switched to placebo after 20 weeks on semaglutide 2.4 mg, approximately two-thirds of lost weight was regained over 48 additional weeks, with partial reversal of metabolic benefits (blood pressure, lipid profile, HbA1c).

This observation is consistent with the modern conceptualization of obesity as a chronic, heterogeneous, and relapsing disease, whose pathophysiology includes resistance to weight loss mediated by adaptive hormonal alterations (leptin, ghrelin, PYY), adaptive thermogenesis, and neural weight memory. The analogous model is hypertension or dyslipidemia: pharmacologic treatment, when indicated, tends to be continuous.

The literature discusses planned transition strategies: gradual dose reduction, intensification of behavioral/nutritional intervention, and close follow-up in the first months of discontinuation. Potential pharmacologic alternatives (class switching, combinations) are also discussed in selected cases.

Perspectives: CagriSema, retatrutide, and the next generation

The metabolic therapeutic landscape is evolving rapidly. CagriSema (cagrilintide + semaglutide) combines a long-acting amylin agonist (cagrilintide) with semaglutide, seeking superior efficacy with maintained gastrointestinal acceptability. The REDEFINE trials (Novo Nordisk) released preliminary results in 2024-2025 with substantial weight loss.

Retatrutide (Eli Lilly) is a triple GLP-1/GIP/glucagon agonist in phase III. Phase II studies (Jastreboff et al., NEJM 2023) demonstrated weight loss of up to 24.2% in 48 weeks with a 12 mg dose — an unprecedented result in the class. The glucagon component adds thermogenesis and hepatic lipid mobilization effects.

Other molecules in development include: orforglipron (non-peptide oral GLP-1 agonist, Eli Lilly), survodutide (dual GLP-1/glucagon agonist, Boehringer), MariTide (long-acting GLP-1 agonist + GIP antagonist, Amgen), and higher-dose semaglutide formulations (7.2 mg in STEP UP). The field is moving toward incretin polypharmacology with increasing efficacy and refined tolerance profiles.

Conclusion: position of Semaglutide in contemporary metabolic medicine

Semaglutide has established itself as the first molecule of a new therapeutic paradigm: a long-acting incretin drug with documented efficacy across three clinically independent dimensions — glycemic control (SUSTAIN), weight loss (STEP), and cardiovascular prevention (SELECT). Few drugs in recent decades have gathered such robust evidence on three hard endpoints simultaneously.

Rapid therapeutic adoption and growing population demand have also brought challenges: intermittent shortages, cultural appropriation of "Ozempic" as a lay synonym for weight loss, ethical concerns about equitable access and marketing, and risks associated with compounded versions. Editorial caution, non-prescriptive language, and emphasis on the irreplaceable role of individualized professional follow-up are pillars of responsible scientific communication.

The content of this page is strictly educational, reviewed against primary literature, and updated as new evidence consolidates. Individualization, clinical assessment, and shared decision-making remain central to any real-world application.